- Investing.com
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
RNA Editing Pionee | Wave Life Sciences leads in RNA editing oligonucleotides, targeting genetic diseases with a diverse pipeline and promising early-stage results in key programs |
AATD Breakthrough | Explore WVE-006's potential for monthly dosing in alpha-1 antitrypsin deficiency, with favorable regulatory pathways and encouraging safety data |
Obesity Market Entry | Delve into Wave's unique INHBE-targeting approach for obesity treatment, offering potential yearly dosing and differentiation in a competitive landscape |
Financial Outlook | Analyst price targets range from $9 to $36, with a consensus "Strong Buy" recommendation despite near-term profitability challenges |
Metrics to compare | WVE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWVEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.1x | −3.4x | −0.7x | |
PEG Ratio | 0.31 | 0.02 | 0.00 | |
Price/Book | 10.3x | 1.5x | 2.6x | |
Price / LTM Sales | 15.3x | 2.9x | 3.4x | |
Upside (Analyst Target) | 110.2% | 7.6% | 39.1% | |
Fair Value Upside | Unlock | 18.8% | 5.5% | Unlock |